Don't fall for the 'next best action' trap

OKRA 15 September, 2020. London, UK.
OKRA has announced a new, free webinar called 'Why Next Best Action is not enough', a panel will discuss the urgent need to move beyond the current trend of adding simplistic or 'dumb' AI tools to sales force dashboards.

These AI tools make sense for managers - they are very easy to apply, inexpensive, and give reps an enhanced view of the market - but in the medium-to-long term will likely cause more harm than good.

During the webinar we will discuss why we must immediately take more care when installing these systems. In particular, we must avoid three common traits:

Autocratic

Most of us would recoil in fear if we were told that our next manager was going to be an autocrat. We would far rather a boss who used carrots rather than sticks to motivate his/her workforce. We would value empathy and flexibility in our leadership: ultimately it's preferable to have someone we want to work for.

Yet the next best action systems are very much the opposite. They bark out single-line instructions that come with very little nuance. Even if they are right, it won't take long for us to want to 'rage against the machine'.

Unexplained

The vast majority of AI systems being deployed are 'black box'. And there's a very good reason for that: AI systems learn as they go, and it eventually becomes more and more difficult to understand their reasoning. In fact, the more sophisticated and intelligent the AI, the harder it is to explain the decisions it makes.

But like the autocratic manager, we quickly lose trust and respect if we cannot break down our actions or decisions into rational arguments.

Dumb

There are different grades of AI. Many of the systems being deployed currently are 'rules-based systems' - where an inferior artificial intelligence is given guidelines and parameters to work with, in order that it can figure out what it needs to.

And you would think that by setting up such a scenario, you would be helping the AI, a little bit like adding stabilisers onto a child’s bicycle to stop them falling over.

However it is also easy to understand that nobody would ever compete in the Tour de France with stabilisers on their bike. These stabilisers would stop you ever from becoming an elite cyclist, and rules-based systems are similarly unable to become as smart as we require.

Non-rules based systems, or 'deep' AI, are far more difficult to create. Typically, such systems are not even told the rules of the game when they start playing. However they quickly supersede their counterparts and become insightful - and useful.

Ultimately, it’s about trust

Our industry has experienced countless 'digital transformation' initiatives that have failed to get off the ground. Often that's not because of the sophistication of the technology but because of the lack of belief or trust in the system. Next best action systems are no different in this regard.

Join this free webinar to witness the solution - what is possible - and how to avoid these common pitfalls that could otherwise result in a lot of wasted money, morale and a lack of interest in engaging with future solutions.

For durther information and to register, please visit:
https://okra.ai/webinar

About OKRA

At OKRA we are fostering a new generation of ArtificiaI Intelligence (AI) solutions that support the healthcare ecosystem. Our solutions are implemented by top pharma companies throughout the product pipeline to empower employees in decision making around complex problems.

OKRA's AI solutions are translating large clinical, scientific and commercial data sets into actionable insights that employees in life science companies can easily query at their desks or whilst on the move.

We believe that for AI to truly empower people, the insights presented must be explainable and instil confidence when driving action. Our suite of products have been built in partnership with top life science companies, with a focus on empowering the people to take action.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...